Epidemiology of Helicobacter in Chinese families: a foundation for cost-effective eradication strategies?

and ‘Large-scale, national, family-based epidemiological study on Helicobacter pylori infection in China: the time to change practice for related disease prevention’ will encourage more doctors in China to consider Helicobacter pylori as a curable aetiology for gastrointestinal symptoms, and as a smart way to prevent gastric cancer in the ageing population.

The paper is based on results of a very large new study of H. pylori prevalence in China whereby investigators completed a China-wide breath-test survey of 10735 families. Unfortunately, 70% of families had at least one positive family member although younger, educated and Eastern-China families had less, with 28% of persons being infected but only 20% of children being infected. In contrast, some North-Western provinces had 85% of families infected and 19% had all family members infected. The parents seemed to be the main source, mother and father equally. Food serving habits had only a very minor effect on prevalence.

H. pylori is the primary cause of gastric cancer, which is still the fourth most common cause of cancer-related death. Every year, about 1 089 103 of new gastric cancer cases are diagnosed worldwide and about 478 508 cases are located in China alone. In China, the H. pylori prevalence is lower (30%–50%) along the wealthiest coastal cities and higher (50%–80%) among the inner cities. Gansu, one of the poorest provinces in China, has the highest prevalence of H. pylori and the highest incidence of gastric cancer. But globally, the correlation does not always hold. India and Bangladesh are known to have a high prevalence of H. pylori but a low incidence of gastric cancer. Conversely, people in Korea, Japan and China, who carry the H. pylori strains with the most potent CagA toxin, have the most gastric cancer. This suggests that factors such as H. pylori strain variance, human host genetic profiles and diet also contribute to gastric cancer.

While the exact mechanism whereby H. pylori causes gastric cancer is unknown, it is certain that gastric cancer follows the long-standing chronic gastritis induced by H. pylori. This process leads to the Correa cascade of atrophic gastritis, intestinal metaplasia and dysplasia. Nested case–control studies have shown that H. pylori infection is the main risk factor for gastric cancer, both intestinal and diffuse subtype, and that H. pylori is responsible for approximately 90% of the world’s burden of non-cardia gastric cancer.

Evidence exists that eradication of H. pylori is a cost-effective strategy to reduce gastric cancer. In the Matsu Islands of Taiwan, mass screening and eradication of H. pylori has decreased gastric cancer by approximately 25%, peptic ulcers by two-thirds, and gastric atrophy by 77% compared with historical data. However, as antibiotic resistance is rising globally, China is facing a challenge in tackling antibiotic resistant H. pylori strains. At this time, only a handful of hospitals/laboratories in China have the capability of culturing H. pylori. The poor success rate in H. pylori cultivating makes it difficult to implement a ‘precision medicine’ strategy to choose the most efficient antibiotics to treat individuals with antibiotic resistant H. pylori. Since there is no fool-proof guideline to direct antibiotic use after failing the first-line standard triple therapy, clinicians are inclined to treat patients blindly by prescribing random antibiotics, that is, ‘making a guess’.

China is a country burdened with a high prevalence of gastric cancer and H. pylori eradication has been shown to be worthwhile in many studies. The task of finding and eradicating H. pylori, within families, should not be delayed.

Barry Marshall

1 Helicobacter pylori Research Laboratory, School of Biomedical Sciences, Marshall Centre for Infectious Disease Research and Training, The University of Western Australia Faculty of Health and Medical Sciences, Perth, Western Australia, Australia
2 Marshall Laboratory of Biomedical Engineering, School of Biomedical Engineering, Shenzhen University, Shenzhen, Guangdong, China

Correspondence to Professor Barry Marshall, Helicobacter Pylori Research Laboratory, School of Biomedical Sciences, Marshall Centre for Infectious Disease Research and Training, The University of Western Australia Faculty of Health and Medical Sciences, Perth, Western Australia, Australia; barry.marshall@uw.edu.au

Contributors BM is the sole contributor of this work.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; internally peer reviewed.

OPEN ACCESS

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite Marshall B. Gut Epub ahead of print: [please include Day Month Year]. doi:10.1136/gutjnl-2023-329786

Received 26 February 2023
Accepted 14 March 2023

Gut 2023;0:1. doi:10.1136/gutjnl-2023-329786

ORCID iD Barry Marshall http://orcid.org/0000-0003-4853-5015

REFERENCES